Interestingly, in our analysis, we found a significant increase of FEZ1 mRNA levels in BD responders versus non-responders (FC = 1.51; p-value = 0.0314), suggesting FEZ1 as a potential target of Li therapeutic effects. This evidence concerns the gene FEZ1 and Behcet disease.